Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)

Plain-language summary

This observational study investigates secondary cancers that develop in patients with Philadelphia-negative myeloproliferative neoplasms - polycythemia vera, essential thrombocythemia and myelofibrosis. It is not a drug trial; the course of these JAK2V617F-associated conditions was examined, and patients diagnosed between 2000 and 2016 were included. This was a phase-not-applicable study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Intervention

JAK2V617F mutation

Start date

5/15/2018

Estimated completion

9/30/2018

Countries

Czechia, Germany, Israel, Italy, Spain, United Kingdom

Related genes

Locations

• Olomouc, Czechia
• Aachen, Germany
• Minden, Germany
• Kfar Saba, Israel
• Asti, Italy
• Bergamo, Italy
• Bologna, Italy
• Catania, Italy
• Cuneo, Italy
• Florence, Italy
• Milan, Italy
• Milan, Italy
• Monza, Italy
• Naples, Italy
• Novara, Italy
• Pavia, Italy
• Reggio Emilia, Italy
• Roma, Italy
• Torino, Italy
• Torino, Italy
• Verona, Italy
• Vicenza, Italy
• Barcelona, Spain
• Barcelona, Spain
• Barcelona, Spain
• Santiago de Compostela, Spain
• Valencia, Spain
• Zaragoza, Spain
• Belfast, United Kingdom
• London, United Kingdom

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Diagnosis of Philadelphia-negative Myeloproliferative Neoplasms (MPN) according to PVSG, 2008 and 2016 WHO criteria, including:
* Polycythemia Vera (PV)
* Essential Thrombocythemia (ET)
* Myelofibrosis (MF), including both primary and secondary MF
* Diagnosis performed between 1st January 2000 to 31 December 2016
* Diagnosis of secondary cancer(s) performed concurrently or subsequently the diagnosis of MPN

Exclusion Criteria:

\- Diagnosis of cancer occurred before the diagnosis of MPN (PV, ET, MF)